Large-Scale Multicenter Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
June 2023
in “
Advances in therapy
”
Studysummary In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer